Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company ...

Reports Q3 revenue $213M, consensus $210.73M. “During the third quarter of 2024, we grew revenue by 11%, compared to the third quarter of ...

Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...